Cyclacel Pharmaceuticals Files 8-K Report
Ticker: BGMSP · Form: 8-K · Filed: May 6, 2025 · CIK: 1130166
Sentiment: neutral
Topics: material-agreement, filing, corporate-action
Related Tickers: CYCC
TL;DR
Cyclacel Pharma filed an 8-K on May 6th, expect news.
AI Summary
On May 6, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Xcyte Therapies Inc., is incorporated in Delaware and has its principal executive offices in Berkeley Heights, NJ.
Why It Matters
This 8-K filing indicates significant corporate activity or agreements by Cyclacel Pharmaceuticals, Inc., requiring public disclosure.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for a material definitive agreement and does not inherently indicate high risk.
Key Numbers
- 0-50626 — Commission File Number (SEC Filing Identifier)
- 91-1707622 — I.R.S. Employer Identification Number (Company Tax Identifier)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former Company Name
- May 6, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Berkeley Heights, NJ (location) — Business Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report the entry into a material definitive agreement, along with Regulation FD disclosures and financial statements and exhibits.
When was this 8-K report filed?
The report was filed on May 6, 2025.
What was Cyclacel Pharmaceuticals, Inc. formerly known as?
The company was formerly known as XCYTE THERAPIES INC.
In which state is Cyclacel Pharmaceuticals, Inc. incorporated?
The company is incorporated in Delaware.
What is the business address of Cyclacel Pharmaceuticals, Inc.?
The business address is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).